Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib in cfDNA BRAF Mutated Metastatic Melanoma
NCT05299580Phase 2Withdrawn
- Start
- Feb 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma. Planned start Feb 2021; status: withdrawn.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05299580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299580.